AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid the easing of COVID-19 restrictions. Revenue growth was driven by new product launches and a steady contribution from licensing deals, particularly the international rollout of Maxigesic oral and intravenous formulations. Reported operating profit of NZ$20.4m was slightly higher than our estimate of NZ$19.4m. AFT announced plans to initiate a dividend ....
25 May 2022
AFT Pharmaceuticals - Recovery driven by strong H222
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AFT Pharmaceuticals - Recovery driven by strong H222
AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid the easing of COVID-19 restrictions. Revenue growth was driven by new product launches and a steady contribution from licensing deals, particularly the international rollout of Maxigesic oral and intravenous formulations. Reported operating profit of NZ$20.4m was slightly higher than our estimate of NZ$19.4m. AFT announced plans to initiate a dividend ....